Advertisement

Treatment of Perianal Crohn Disease Fistulae

  • Mark T. Osterman
  • Gary R. Lichtenstein

Keywords

Inflammatory Bowel Disease Crohn Disease Anal Fistula Rectovaginal Fistula Perianal Fistula 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. JAMA 1932;99:1323–9.Google Scholar
  2. 2.
    Bissell AD. Localized chronic ulcerative colitis. Ann Surg 1934;99:957–66.Google Scholar
  3. 3.
    American Gastroenterological Association. American Gastroenterological Association medical position statement: perianal Crohn disease. Gastroenterology 2003;125:1503–7.Google Scholar
  4. 4.
    American Gastroenterological Association. AGA technical review on perianal Crohn disease. Gastroenterology 2003;125:1508–30.CrossRefGoogle Scholar
  5. 5.
    Scott HJ, Northover JM. Evaluation of surgery for perianal Crohn fistulas. Dis Colon Rectum 1996;39:1039–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003;9:98–103.PubMedCrossRefGoogle Scholar
  7. 7.
    Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rates in fistulizing anorectal Crohn disease: a single center experience. Dis Colon Rectum 2003;46:577–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn disease. Aliment Pharmacol Ther 2003;17:1145–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz DA, Herdman CR. Review article: the medical treatment of Crohn perianal fistulas. Aliment Pharmacol Ther 2004;19:953–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Hughes L. Surgical pathology and management of anorectal Crohn disease. J R Soc Med 1978;71:644–51.PubMedGoogle Scholar
  11. 11.
    Parks A. The pathogenesis and treatment of fistula-in-ano. Br Med J 1961;1:463–9.Google Scholar
  12. 12.
    Fielding JF. Perianal lesions in Crohn disease. J R Coll Surgeons Edinb 1972;17:32–7.Google Scholar
  13. 13.
    Greenstein AJ, Kark AE, Drelling DA. Crohn disease of the colon I. Fistula in Crohn disease colon, classification presenting features and management in 63 patients. Am J Gastroenterol 1974;62:419–29.PubMedGoogle Scholar
  14. 14.
    Farmer R, Hawk W, Turnbull RJ. Clinical patterns in Crohn disease. A statistical study of 615 cases. Gastroenterology 1975;68:627–35.PubMedGoogle Scholar
  15. 15.
    Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National Cooperative Crohn Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914–20.PubMedGoogle Scholar
  16. 16.
    Buchmann P, Keighly MR, Allan RN, Thompson H, Alexander-Williams J. Natural history of perianal Crohn disease. Ten year follow-up: a plea for conservatism. Am J Surg 1980;140:642–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn disease. Dis Colon Rectum 1981;24:22–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Marks CG, Ritchie JK, Lockhart-Mummery HE. Anal fistulas in Crohn disease. Br J Surg 1981;68:525–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hobbiss JH, Schofield PF. Management of perianal Crohn disease. J R Soc Med 1982;75:414–7.PubMedGoogle Scholar
  20. 20.
    Van Dongen LM, Lubbers E. Perianal fistulas in patients with Crohn disease. Arch Surg 1986;121:1187–90.PubMedGoogle Scholar
  21. 21.
    Goebell H. Perianal complications in Crohn disease. Neth J Med 1990;37:S47–51.PubMedGoogle Scholar
  22. 22.
    Hellers G, Bergstrand O, Ewerth S, Homstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn disease. Gut 1980;21:525–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Schwartz DA, Loftus EV, Tremaine WJ, Pananccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn disease in Olmstead County, Minnesota. Gastroenterology 2002;122:875–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Gray BK, Lockhart-Mummery HE, Morson BC. Crohn disease of the anal region. Gut 1965;6:515–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn disease. Dis Colon Rectum 1995;38:55–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn disease. Gastroenterol Clin N Am 2004;33:421–54.Google Scholar
  27. 27.
    Bayer I, Gordon PH. Selected operative management of fistula-in-ano in Crohn disease. Dis Colon Rectum 1994;37:760–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn disease. Dis Colon Rectum 1997;40:443–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Van Beers B, Grandin C, Kartheuser A. MRI of complicated anal fistulae: comparison with digital examination. J Comput Assist Tomogr 1994;18:87–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Fazio VW, Wilk P, Turnbull RB Jr, Jagelman DG. The dilemma of Crohn disease: ileosigmoidal fistula complicating Crohn disease. Dis Colon Rectum 1977;20:381–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Kuijpers HC, Schulpen T. Fistulography for fistula-in-ano. Is it useful? Dis Colon Rectum 1985;28:103–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Glass RE, Ritchie JK, Lennard-Jones JE, Hawley PR, Todd IP. Internal fistulas in Crohn disease. Dis Colon Rectum 1985;28:557–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Pomerri F, Pittarello F, Dodi G, Pianon P, Muzzio PC. Radiologic diagnosis of anal fistulae with radio-opaque markers. Radiologia Med 1988;75:632–7.Google Scholar
  34. 34.
    Weisman RI, Orsay CP, Pearl RK, Abcarian H. The role of fistulography in fistula-in-ano. Report of five cases. Dis Colon Rectum 1991;34:181–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Berliner L, Redmond P, Purow E, Megna D, Scottile V. Computed tomography in Crohn disease. Am J Gastroenterol 1982;77:584–53.Google Scholar
  36. 36.
    Goldberg HI, Gore RM, Margulis AR, Moss AA, Baker EL. Computed tomography in the evaluation of Crohn disease. Am J Roentgenol 1983;140:277–82.Google Scholar
  37. 37.
    Kerber GW, Greenberg M, Rubin JM. Computed tomography evaluation of local and extraintestinal complications of Crohn disease. Gastrointest Radiol 1984;9:143–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Fishman EK, Wolf EJ, Jones B, Bayless TM, Siegelman SS. CT evaluation of Crohn disease: effect on patient management. Am J Roentgenol 1987;148:537–40.Google Scholar
  39. 39.
    Yousem DM, Fishman EK, Jones B. Crohn disease: perirectal and perianal findings at CT. Radiology 1988;167:331–4.PubMedGoogle Scholar
  40. 40.
    Van Outryve MJ, Pelckmans PA, Michielsen PP, Van Maercke YM. Value of tranrectal ultrasonography in Crohn disease. Gastroenterology 1991;101:1171–7.PubMedGoogle Scholar
  41. 41.
    Schratter-Sehn AU, Lochs H, Vogelsang H, Schurawitzki H, Herold C, Schratter M. Endoscopic ultrasonography versus computed tomography in the differential diagnosis of perianorectal complications in Crohn disease. Endoscopy 1993;25:582–6.PubMedGoogle Scholar
  42. 42.
    Koelbel G, Schmiedl U, Majer MC, Weber P, Jenss H, Kueper K, Hess CF. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. Am J Roentgenol 1989;152:999–1003.Google Scholar
  43. 43.
    Skalej M, Makowiec F, Weinlich M, Jenss H, Laniado M, Starlinger M. Magnetic resonance imaging in perianal Crohn disease. Dtsch Med Wochenschr 1993;118:1791–6.PubMedGoogle Scholar
  44. 44.
    Lunniss PJ, Barker PG, Sultan AH, Armstrong P, Reznek RH, Bartram CI, Cottam KS, Phillips RK. Magnetic resonance imaging of fistula-in-ano. Dis Colon Rectum 1994;37:708–18.PubMedCrossRefGoogle Scholar
  45. 45.
    Barker PG, Lunniss PJ, Armstrong P, Reznek RH, Cottam KS, Phillips RK. Magnetic resonance imaging of fistula-in-ano: technique, interpretation, and accuracy. Clin Radiol 1994;49:7–13.PubMedCrossRefGoogle Scholar
  46. 46.
    Haggert PJ, Moore NR, Shearman JD, Travis SP, Jewell DP, Mortensen NJ. Pelvic and perianal complications of Crohn disease: assessment using magnetic resonance imaging. Gut 1995;36:407–10.CrossRefGoogle Scholar
  47. 47.
    DeSouza NM, Hall AS, Puni R, Gilderdale DJ, Young IR, Kmiot WA. High resolution magnetic resonance imaging of the anal sphincter using a dedicated endoanal coil. Comparison of magnetic resonance imaging with surgical finding. Dis Colon Rectum 1996;39:926–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Spencer JA, Chapple K, Wilson D, Ward J, Windsor AC, Ambrose NS. Outcome after surgery for perianal fistula: predictive value of MR imaging. Am J Roentgenol 1998;171:403–6.Google Scholar
  49. 49.
    Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandborn WJ. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn perianal fistulas. Gastroenterology 2001;121:1064–72.PubMedCrossRefGoogle Scholar
  50. 50.
    Beets-Tan RG, Beets GL, van der Hoop AG, Kessels AG, Vliegen RF, Baeten CG, van Engelshoven JM. Preoperative MR imaging of anal fistulas: does it really help the surgeon? Radiology 2001;218: 75–84.Google Scholar
  51. 51.
    Tio TL, Mulder CJ, Wijers OB, Sars PR, Tytgat GN. Endosonography of peri-anal and per-colorectal fistula and/or abscess in Crohn disease. Gastrointest Endosc 1990;36:331–6.PubMedGoogle Scholar
  52. 52.
    Wijers O, Tio T, Tytgat G. Endosonography (transrectal and transvaginal) in the assessment of perianorectal fistulas and abscesses: experience with 127 cases. In: Demling L, Fruhmorgan P, eds. Non-neoplastic diseases of the anorectum. Kluwer, London, 1992;65–78.Google Scholar
  53. 53.
    Solomon MJ. Fistulae and abscesses in symptomatic perianal Crohn disease. Int J Colorectal Dis 1996;11:222–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A, Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn disease. Br J Surg 1999;86:360–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Stewart LK, McGee J, Wilson SR. Transperineal and transvaginal sonography of perianal inflammatory bowel disease. Am J Roentgenol 2001;177:627–32.Google Scholar
  56. 56.
    Sloots CE, Felt-Bersma RJ, Poen AC, Cuesta MA, Meuwissen SG. Assessment and classification of fistula-in-ano in patients with Crohn disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis 2001;16:292–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Sparberg M, Kirsner JB. Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 1966;11:865–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Jones JH, Lennard-Jones JF. Corticosteroids and corticotropin in the treatment of Crohn disease. Gut 1966;7:181–7.Google Scholar
  59. 59.
    Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn disease. Clin Gastroenterol Hepatol 2005;3:1215–20.PubMedCrossRefGoogle Scholar
  60. 60.
    Ursing B, Kamme C. Metronidazol for Crohn disease. Lancet 1975;1:775–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perianal Crohn disease with metronidazol. Gastroenterology 1980;79:357–65.PubMedGoogle Scholar
  62. 62.
    Schneider MU, Strobel S, Riemann JF, Demling L. Treatment of Crohn disease with metronidazol. Dtsch Med Wochenschr 1981;106:1126–9.PubMedGoogle Scholar
  63. 63.
    Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazol therapy for perianal Crohn disease: a follow-up study. Gastroenterology 1982;83:383–7.PubMedGoogle Scholar
  64. 64.
    Jakobovits J, Schuster MM. Metronidazol therapy for Crohn disease and associated fistulae. Am J Gastroenterol 1984;79:533–40.PubMedGoogle Scholar
  65. 65.
    Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF. Metronidazol in the treatment of Crohn disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr 1985;110:1724–30.PubMedGoogle Scholar
  66. 66.
    Turunen U, Farkkila M, Seppala K. Long-term treatment of perianal or fistulous Crohn disease with ciprofloxacin. Scand J Gastroenterol Suppl 1989;24:144.Google Scholar
  67. 67.
    Wolf JL. Ciprofloxacin may be useful in Crohn disease (abstr). Gastroenterology 1990;98:A212.Google Scholar
  68. 68.
    Solomon MJ, McLeod RS, O’Connor BI, Steinhart AH, Greenberg GR, Cohen Z. Combination ciprofloxacin and metronidazol in severe perianal Crohn disease. Can J Gastroenterol 1993;7:571–3.Google Scholar
  69. 69.
    Turunen U, Farkkila M, Valtonen V. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn disease (abstr). Gastroenterology 1993;104:A793.Google Scholar
  70. 70.
    Freeman CD, Klutman NE, Lamp KC. Metronidazol. A therapeutic review and update. Drugs 1997;54:679–708.PubMedGoogle Scholar
  71. 71.
    Davis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996;51:1019–74.PubMedGoogle Scholar
  72. 72.
    Casparian JM, Luchi M, Moffat RE, Hinthorn D. Quinolones and tendon ruptures. South Med J 2000;93:488–91.PubMedGoogle Scholar
  73. 73.
    Brooke BN, Hoffman DC, Swarbrick ET. Azathioprine for Crohn disease. Lancet 1969;2:612–4.PubMedCrossRefGoogle Scholar
  74. 74.
    Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn disease. Lancet 1971;2:944–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn disease. Lancet 1971;2:1273–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn disease with azathioprine: a controlled evaluation. Gastroenterology 1974;66:916–22.PubMedGoogle Scholar
  77. 77.
    Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn disease. Am J Digest Dis 1975;20:721–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn disease with mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Pearson D, May G, Fick G, Sutherland L. Azathioprine and 6-mercaptopurine in Crohn disease: a meta analysis. Ann Intern Med 1995;123:132–42.PubMedGoogle Scholar
  80. 80.
    Korelitz BI, Present DH. Favorable effect of mercaptopurine on fistulae of Crohn disease. Digest Dis Sci 1985;30:58–64.PubMedCrossRefGoogle Scholar
  81. 81.
    Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn disease in children. J Clin Gastroenterol 2000;30:294–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn disease. Aliment Pharmacol Ther 2003;18:1113–20.PubMedCrossRefGoogle Scholar
  83. 83.
    Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn disease perianal fistulae. Gastroenterology 2001;120:1640–56.PubMedCrossRefGoogle Scholar
  84. 84.
    Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006;130:1047–53.PubMedCrossRefGoogle Scholar
  85. 85.
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641–9.PubMedGoogle Scholar
  86. 86.
    Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Vandeputte L, D’Haens G, Beart F, Rutgeerts P. Methotrexate in refractory Crohn disease. Inflamm Bowel Dis 1999;5:11–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn disease: a case series. Aliment Pharmacol Ther 2003;18:1003–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423–33.PubMedGoogle Scholar
  90. 90.
    Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC. Methotrexate in Crohn disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730–4.PubMedGoogle Scholar
  91. 91.
    Fukushima T, Sugita A, Masuzawa S, Yamazaki Y, Tsuchiya S. Effects of cyclosporine A on active Crohn disease. Gastroenterol Jpn 1989;24:12–5.PubMedGoogle Scholar
  92. 92.
    Lichtiger S. Cyclosporin therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med 1990;57:315–9.PubMedGoogle Scholar
  93. 93.
    Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn disease. Gastroenterology 1990;99:1347–51.PubMedGoogle Scholar
  94. 94.
    Hanauer SB, Smith MB. Rapid closure of Crohn disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993;88:646–9.PubMedGoogle Scholar
  95. 95.
    Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn disease. Dig Dis Sci 1994;39:374–80.PubMedCrossRefGoogle Scholar
  96. 96.
    Abreu-Martin J, Vasilauskas E, Gaiennie J, Voigt B, Targan SR. Continuous infusion cyclosporine is effective for acute severe Crohn disease...but for how long (abstr)? Gastroenterology 1996;110:A851.Google Scholar
  97. 97.
    O’Neill J, Pathmakanthan S, Goh J, Costello S. MacMathuna P, O’Connell R, Crowe J, Lennon J. Cyclopsorine A induces remission in fistulous Crohn disease but relapses occur upon cessation of treatment (abstr). Gastroenterology 1997;112:A1056.CrossRefGoogle Scholar
  98. 98.
    Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs GJ. Combination of cyclosporine, azathioprine and prednisone for perianal fistulas in Crohn disease. Z Gastroenterol 1997;35:603–8.PubMedGoogle Scholar
  99. 99.
    Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn disease with intravenous cyclosporine. Am J Gastroenterol 1998;93:442–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Gurudu SR, Griffel LH, Gialanella RJ, Das KM. Cyclosporine therapy in inflammatory bowel disease: short- and long-term results. J Clin Gastroenterol 1999;29:151–4.PubMedCrossRefGoogle Scholar
  101. 101.
    Present DH. Crohn fistula: current concepts in management. Gastroenterology 2003;124:1629–35.PubMedCrossRefGoogle Scholar
  102. 102.
    Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48–63.CrossRefGoogle Scholar
  103. 103.
    Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn disease. Am J Gastroenterol 1997;92:876–9.PubMedGoogle Scholar
  104. 104.
    Fellerman K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998;93:1860–6.CrossRefGoogle Scholar
  105. 105.
    Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn disease perianal fistulae. Inflamm Bowel Dis 1999;5:239–45.PubMedCrossRefGoogle Scholar
  106. 106.
    Ierardi E, Principi M, Rendina M, Francavilla R, Ingrosso M, Pisani A, Amoruso A, Panella C, Francavilla A. Oral tacrolimus (FK506) in Crohn disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000;125:30:200–2.CrossRefGoogle Scholar
  107. 107.
    Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn disease: a randomized, placebo-controlled trial. Gastroenterology 2003;125:380–88.PubMedCrossRefGoogle Scholar
  108. 108.
    Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn disease: a pilot study. Inflamm Bowel Dis 2005;11:8–15.PubMedCrossRefGoogle Scholar
  109. 109.
    Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469–77.PubMedCrossRefGoogle Scholar
  110. 110.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn disease. Am J Gastroenterol 2000;95:3490–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infliximab for the treatment of fistulas in patients with Crohn disease. N Engl J Med 1999;340:1398–405.PubMedCrossRefGoogle Scholar
  113. 113.
    Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn disease. N Engl J Med 2004;350:876–85.PubMedCrossRefGoogle Scholar
  114. 114.
    Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004;2:912–20.PubMedCrossRefGoogle Scholar
  115. 115.
    Cadahia V, Garcia-Carbonero A, Vivas S, Fuentes D, Nino P, Rebollo P, Rodrigo L. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn disease in clinical practice. Rev Esp Enferm Dig 2004;96:369–74.PubMedGoogle Scholar
  116. 116.
    Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalization, surgeries, and procedures in fistulizing Crohn disease. Gastroenterology 2005;128: 862–9.PubMedCrossRefGoogle Scholar
  117. 117.
    Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Lyhne Nielsen S, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn disease. Aliment Pharmacol Ther 2003;17:703–10.PubMedCrossRefGoogle Scholar
  118. 118.
    Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn disease. Dis Colon Rectum 2002;45:771–5.PubMedCrossRefGoogle Scholar
  119. 119.
    West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJF, van Tilburg AJP, Drapers JAG, Kuipers EJ. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004;20:1329–36.PubMedCrossRefGoogle Scholar
  120. 120.
    Ochsenkühn T, Göke B, Sackmann M. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn disease. Am J Gastroenterol 2002;97:2022–5.PubMedGoogle Scholar
  121. 121.
    Schröder O, Blumenstein I, Schulte-Buckholt A, Stein J. Combining infliximab and methotrexate in fistulizing Crohn disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 2004;19: 295–301.Google Scholar
  122. 122.
    Van der Hagen SJ, Baeten CG, Soeters PB, Russel MGVM, Beets-Tan RG, van Gemert WG. Anti-TNF-α (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn disease: a preliminary report. Dis Colon Rectum 2005;48:758–67.PubMedCrossRefGoogle Scholar
  123. 123.
    Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn disease. Colorectal Disease 2005;7:164–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119–33.PubMedCrossRefGoogle Scholar
  125. 125.
    Schaible TF. Long-term safety of infliximab. Can J Gastroenterol 2000;14:29C-32C.PubMedGoogle Scholar
  126. 126.
    Remicade (infliximab) for IV injection. Package Insert, 2002.Google Scholar
  127. 127.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–104.PubMedCrossRefGoogle Scholar
  128. 128.
    Morelli J, Wilson FA. Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 2000;95:841–2.PubMedCrossRefGoogle Scholar
  129. 129.
    Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002;34:410–2.PubMedCrossRefGoogle Scholar
  130. 130.
    Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099–100.PubMedCrossRefGoogle Scholar
  131. 131.
    Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78.PubMedCrossRefGoogle Scholar
  132. 132.
    Sandborn WJ, Hanauer SB, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn disease. Am J Gastroenterol 2004;99:1984–9.PubMedCrossRefGoogle Scholar
  133. 133.
    Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CD, Salzberg B, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Hanauer SB. A randomized, double-blind, placebo-controlled multicenter trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn disease (abstr). Gastroenterology 2000;118:A655.CrossRefGoogle Scholar
  134. 134.
    Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120:1330–8.PubMedCrossRefGoogle Scholar
  135. 135.
    Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn disease: an open-label trial. Gastroenterology 1999;117:1271–7.PubMedCrossRefGoogle Scholar
  136. 136.
    Vasilauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn disease. Gastroenterology 1999;117:1278–87.CrossRefGoogle Scholar
  137. 137.
    Voitk AJ, Echave V, Brown RA, Gurd FN. Use of elemental during the adaptive stage of short gut syndrome. Gastroenterology 1973;65:419–26.PubMedGoogle Scholar
  138. 138.
    Segal AW, Levi AJ, Loewi G. Levamisole in the treatment of Crohn disease. Lancet 1977;2:382–5.PubMedCrossRefGoogle Scholar
  139. 139.
    Axelsson C, Jarnum S. Assessment of the therapeutic value of an elemental diet in chronic inflammatory bowel disease. Scand J Gastroenterol 1977;12:89–95.PubMedGoogle Scholar
  140. 140.
    Russell RI, Hall MJ. Elemental diet therapy in the management of complicated Crohn disease. Scott Med J 1979;24:291–5.PubMedGoogle Scholar
  141. 141.
    Calam J, Crooks PE, Walker RJ. Elemental diets in the management of Crohn perianal fistulae. J Parenter Enteral Nutr 1980;4:4–8.CrossRefGoogle Scholar
  142. 142.
    Jones VA. Comparison of total parenteral nutrition and elemental diet in induction of remission of Crohn disease. Dig Dis Sci 1987;32:100S-107S.PubMedCrossRefGoogle Scholar
  143. 143.
    Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn disease. J Gastroenterol 1995;30:83–7.PubMedCrossRefGoogle Scholar
  144. 144.
    Harford FJ, Fazio VW. Total parenteral nutrition as primary therapy for inflammatory bowel disease of the bowel. Dis Colon Rectum 1978;21:555–7.PubMedCrossRefGoogle Scholar
  145. 145.
    Milewski PJ, Irving MH. Parenteral nutrition in Crohn disease. Dis Colon Rectum 1980;23:395–400.PubMedCrossRefGoogle Scholar
  146. 146.
    Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn disease. Gut 1988;29: 1309–15.Google Scholar
  147. 147.
    Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycopheylate mofetil in patients with Crohn disease. Am J Gastroenterol 1998;93:2529–32.PubMedCrossRefGoogle Scholar
  148. 148.
    Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn disease. N Engl J Med 1999;340:239–40.PubMedCrossRefGoogle Scholar
  149. 149.
    Korzenik J, Dieckgraefe B. Immunostimulation in Crohn disease: results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn disease (abstr). Gastroenterology 2000;118:A874.CrossRefGoogle Scholar
  150. 150.
    Dieckgraefe BK, Korzenik JR. Treatment of active Crohn disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002;360:1478–80.PubMedCrossRefGoogle Scholar
  151. 151.
    Brady CE III, Cooley BJ, Davis JC. Healing of severe perianal and cutaneous Crohn disease with hyperbaric oxygen. Gastroenterology 1989;97:756–60.PubMedGoogle Scholar
  152. 152.
    Nelson EW Jr, Bright DE, Villar LF. Closure of refractory perianal Crohn lesion. Integration of hyperbaric oxygen into case management. Dig Dis Sci 1990;35:1561–6.PubMedCrossRefGoogle Scholar
  153. 153.
    Brady CE III. Hyperbaric oxygen and perianal Crohn disease: a follow-up. Gastroenterology 1993;105:1264.PubMedGoogle Scholar
  154. 154.
    Lavy A, Weisz G, Adir Y, Ramon Y, Melamed Y, Eidelman S. Hyperbaric oxygen for perianal Crohn disease. J Clin Gastroenterol 1994;19:202–5.PubMedCrossRefGoogle Scholar
  155. 155.
    Colombel JF, Mathieu D, Bouault JM, Lesage X, Zavadil P, Quandalle P, Cortot A. Hyperbaric oxygen in severe perianal Crohn disease. Dis Colon Rectum 1995;38:609–14.PubMedCrossRefGoogle Scholar
  156. 156.
    Oshitani N, Nakamura S, Matsumoto T, Kobayashi K, Kitano A. Treatment of Crohn disease fistulas with coagulation factor XIII. Lancet 1996;347:119–20.PubMedCrossRefGoogle Scholar
  157. 157.
    Teahon K, Bjarnason I, Pearson M, Levi AJ. Ten years’ experience with an elemental diet in the management of Crohn disease. Gut 1990;31:1133–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Mark T. Osterman
  • Gary R. Lichtenstein
    • 1
  1. 1.Division of GastroenterologyHospital of the University of Pennsylvania, University of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations